Immunovia’s vision is to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
IMMray™ PanCan-d is the first blood-based test dedicated to early detection of pancreatic cancer. It is exclusively available as a laboratory developed test (LDT) from Immunovia, Inc., Marlborough, USA.
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see www.immunoviainc.com.
Immunovia has initiated since 2016 a prospective clinical validation program for high risk groups for pancreatic cancer involving 30 hospitals and over 10,000 patients from USA and Europe.
Listen to Immunovia’s conference call related to the planned changes announced on July 11, 2023.
Immunovia AB published the company’s Interim Report January-March 2023 on Tuesday, May 23, 2023, at 8:30 am CET.